“We have international collaborators and now have more than a thousand brain mets in our bank that we’re going to analyze,” says neuro-oncologist Priscilla K. Brastianos, MD.
Departments, Centers, & Programs:
Pappas Center for Neuro Oncology
55 Fruit Street
Boston, MA 02114
Mass General Waltham
52 Second Avenue
Waltham, MA 02451
- MD, Emory University School of Medicine
- MPH, Harvard T. H. Chan School of Public Health
- Residency, Massachusetts General Hospital
- Fellowship, Memorial Hospital for Cancer and Allied Diseases
American Board Certifications
- Neurology, American Board of Psychiatry and Neurology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
A major emphasis of my research has been the development and implementation of experimental therapeutics for glioblastomas with an emphasis on targeted drugs. These studies serve as the basis of my NIH grants and all of my investigator-initiated trials include correlative biospecimen and imaging studies in collaboration with multiple HMS investigators. Our studies of cediranib, a pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor have led to important insights regarding the mechanism of action of VEGF inhibitors in glioblastomas. My initial NCI-funded study of cediranib in recurrent glioblastoma has led to additional studies including an R01-funded phase Ib/II study in newly diagnosed glioblastoma.
Another component of my clinical research has focused on clinical investigations and therapeutic trials in primary central nervous system lymphoma (PCNSL). I have served as principal investigator for institutional as well as NCI-sponsored multi-institutional trials of PCNSL. I am also the co-founder and co-chair of the International PCNSL Collaborative Group (IPCG), an international, multidisciplinary group of 120 investigators from 15 countries with research interests in this disease. I serve as the PI of an NCI-sponsored R13 grant that funds the annual IPCG meeting and I have led or participated in multiple international studies within this group. I am the editor of the only textbook dedicated exclusively to CNS lymphoma, which will be published in a 2nd edition in 2010.
- Batchelor TT, Betensky RA, Esposito JM, Pham L, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004; 10: 228-233
- Batchelor TT, Carson K, O'Neill A, Alavi J, New P, Grossman SA, Hochberg F, Priet R for the NABTT CNS Consortium. The treatment of primary central nervous system lymphoma (PCNSL) with methotrexate and deferred radiotherapy: NABTT 96-07. J Clin Oncol 2003; 21: 1044-1049
- Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen P-J, Zhu M, Ancukiewicz M, Mrugala M, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF and PDGF receptor tyrosine kinase inhibitor normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95
- Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. MGMT methylation is a prognostic biomarker in elderly patients with new diagnosed glioblastoma. Neurology 2009; 73: 1509-1510
- Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28: 2817-2823